TScan Therapeutics, Inc.
TCRXTScan Therapeutics, Inc. in brief
TScan Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $14 M on 29 October 2026, which makes it the 25,329th largest listed company in the world and the 4,234th largest in the USA on this site. In the year to December 2025 it had sales of $10 M and a net loss of $130 M. It employs about 142 people and Gavin MacBeath is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol TCRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About TScan Therapeutics, Inc.
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual disease and promote complete donor chimerism, thereby preventing relapse. TSC-101 targets HA-2, an antigen that is present on all blood cells, malignant or benign, in patients with the HLA type A*02:01. We are currently conducting a Phase 1 clinical study of TSC-101 (the ALLOHA™ trial, NCT05473910) and during the fourth quarter of 2025, following a productive End-of-Phase meeting with the U.S. Food and Drug Administration (FDA), we reached agreement on a registrational path forward for the TSC-101 program as a potential treatment for patients with AML and MDS. The pivotal study will mirror our ongoing Phase 1 ALLOHA study, using a biologically-assigned (genetically randomized) control arm to support relapse-free survival as the primary endpoint.
From the company's annual report filed with the US SEC: read the report
TScan Therapeutics, Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 19 July 2021; shares registered for exchange trading on 13 July 2021.
- 2023
- 💰Record revenue of $21 millionFY2023, the highest of the 5 years on record.
Events of TScan Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,341 (Jan 2022) · #4,992 (Dec 2022) · #4,229 (Jul 2023) · #3,019 (Jan 2024) · #2,075 (Mar 2026) · #3,742 (Aug 2026) · #4,225 (Oct 2026) · #4,236 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.6×
- Price / book
- 0.1×
- Free cash flow yield
- -1030.5%
- Net margin (TTM)
- -2221.8%
- Operating margin
- -1316.0%
- Return on equity
- -93.5%
- Liabilities / assets
- 46.2%
- Net debt
- $-120M
- Revenue growth
- +266.0%
- R&D / revenue
- 1106.1%
- Revenue per employee
- $73 K
- Profit per employee
- $-914 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $10M | +266.0% | $-136M | $-130M | -1257.5% |
| Dec 2024 | $3M | -86.6% | $-135M | $-128M | -4521.3% |
| Dec 2023 | $21M | +55.5% | $-93M | $-89M | -423.8% |
| Dec 2022 | $14M | +33.5% | $-67M | $-66M | -489.1% |
| Dec 2021 | $10M | — | $-49M | $-49M | -479.5% |
| Dec 2020 | — | — | $-26M | $-26M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-135M | $4M | $-140M | $-1.00 | — |
| Dec 2024 | $-111M | $4M | $-115M | $-1.14 | — |
| Dec 2023 | $-61M | $3M | $-65M | $-1.36 | — |
| Dec 2022 | $-67M | $4M | $-71M | $-2.75 | — |
| Dec 2021 | $-49M | $10M | $-59M | $-4.17 | — |
| Dec 2020 | $-3M | $4M | $-7M | $-28.52 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-76.5% on a year earlier), net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 26, 2026DEF 14AProxy statement
- Oct 16, 20268-KCurrent reportDirectors or officers changed
- Sep 30, 20268-KCurrent reportDirectors or officers changed
- Sep 11, 20268-KCurrent reportDirectors or officers changed
- Sep 2, 20268-KCurrent reportRestructuring costs · Listing notice · Directors or officers changed · Regulation FD disclosure · Other events
- Aug 18, 20268-KCurrent reportAgreement ended
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 22, 20268-KCurrent reportBylaws amended · Shareholder vote
Official filings of TScan Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $10 M
- Operating income
- $-136 M
- Net income
- $-130 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $229 M
- Total liabilities
- $106 M
- Total equity
- $123 M
As of December-2025
Top 52 institutional investors in TScan Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 8,019,148 | 0 (0.00%) | 11.83% | $3 M | Nov 16, 2026 |
| 2 | BVF Inc/il | 5,564,290 | 0 (0.00%) | 8.21% | $2 M | Nov 16, 2026 |
| 3 | Boothbay Fund Management, LLC | 3,400,092 | +2,627,851 (+340.29%) | 5.01% | $1 M | Nov 16, 2026 |
| 4 | Baker Bros. Advisors LP | 2,784,792 | 0 (0.00%) | 4.11% | $1 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 2,508,887 | +350,056 (+16.22%) | 3.70% | $1 M | Nov 13, 2026 |
| 6 | Acadian Asset Management LLC | 1,692,467 | +386,627 (+29.61%) | 2.50% | $1 M | Nov 9, 2026 |
| 7 | Two Sigma Investments, LP | 1,644,246 | -305,358 (-15.66%) | 2.43% | $1 M | Nov 16, 2026 |
| 8 | Deer Management Co. LLC | 1,245,504 | 0 (0.00%) | 1.84% | $0 M | Nov 16, 2026 |
| 9 | Renaissance Technologies LLC | 1,208,199 | -118,600 (-8.94%) | 1.78% | $0 M | Nov 12, 2026 |
| 10 | DC Funds, LP | 630,000 | 0 (0.00%) | 0.93% | $0 M | Nov 13, 2026 |
| 11 | Geode Capital Management, LLC | 604,332 | +19,521 (+3.34%) | 0.89% | $0 M | Nov 6, 2026 |
| 12 | BlackRock, Inc. | 597,865 | -396,789 (-39.89%) | 0.88% | $0 M | Nov 13, 2026 |
| 13 | Gsa Capital Partners LLP | 510,700 | -37,387 (-6.82%) | 0.75% | $0 M | Nov 16, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 363,954 | 0 (0.00%) | 0.54% | $0 M | Nov 13, 2026 |
| 15 | Marshall Wace, LLP | 269,613 | -417,751 (-60.78%) | 0.40% | $0 M | Nov 13, 2026 |
| 16 | Verdad Advisers, LP | 227,259 | -5,500 (-2.36%) | 0.34% | $0 M | Nov 16, 2026 |
| 17 | State Street Corp | 206,600 | -713 (-0.34%) | 0.30% | $0 M | Nov 12, 2026 |
| 18 | Northern Trust Corp | 138,778 | 0 (0.00%) | 0.20% | $0 M | Nov 16, 2026 |
| 19 | UBS Group AG | 108,247 | +39,374 (+57.17%) | 0.16% | $0 M | Nov 10, 2026 |
| 20 | Morgan Stanley | 104,749 | -93,142 (-47.07%) | 0.15% | $0 M | Nov 13, 2026 |
| 21 | Letko, Brosseau & Associates Inc | 95,875 | 0 (0.00%) | 0.14% | $0 M | Nov 6, 2026 |
| 22 | XTX Topco Ltd | 95,163 | -54,304 (-36.33%) | 0.14% | $0 M | Nov 16, 2026 |
| 23 | Jane Street Group, LLC | 90,185 | -151,308 (-62.66%) | 0.13% | $0 M | Nov 12, 2026 |
| 24 | Bridgeway Capital Management, LLC | 75,707 | -1,193 (-1.55%) | 0.11% | $0 M | Nov 16, 2026 |
| 25 | Empowered Funds, LLC | 69,207 | New | 0.10% | $0 M | Nov 13, 2026 |
Show all 52: investors 26 to 52
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | HRT Financial LP | 62,643 | -101,958 (-61.94%) | 0.09% | $0 M | Nov 13, 2026 |
| 27 | Kestra Advisory Services, LLC | 62,525 | 0 (0.00%) | 0.09% | $0 M | Nov 2, 2026 |
| 28 | Goldman Sachs Group Inc | 59,672 | -10,842 (-15.38%) | 0.09% | $0 M | Nov 16, 2026 |
| 29 | Citadel Advisors LLC | 51,756 | -957,351 (-94.87%) | 0.08% | $0 M | Nov 16, 2026 |
| 30 | Bank Of America Corp /de/ | 37,624 | -11,476 (-23.37%) | 0.06% | $0 M | Nov 16, 2026 |
| 31 | DC Investments Management, LLC | 35,563 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 32 | HSBC Holdings PLC | 24,574 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 33 | R Squared Ltd | 21,607 | +3,247 (+17.69%) | 0.03% | $0 M | Nov 6, 2026 |
| 34 | Barclays PLC | 17,081 | -2,089 (-10.90%) | 0.03% | $0 M | Nov 6, 2026 |
| 35 | Vanguard Global Advisers, LLC | 15,705 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 36 | Two Sigma Securities, LLC | 14,054 | New | 0.02% | $0 M | Nov 16, 2026 |
| 37 | AQR Capital Management LLC | 13,866 | New | 0.02% | $0 M | Nov 16, 2026 |
| 38 | Ieq Capital, LLC | 13,723 | New | 0.02% | $0 M | Nov 10, 2026 |
| 39 | Aries Wealth Management | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 23, 2026 |
| 40 | Global Retirement Partners, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 41 | Pathstone Holdings, LLC | 10,000 | New | 0.01% | $0 M | Nov 13, 2026 |
| 42 | Osaic Holdings, Inc. | 9,756 | -2,489 (-20.33%) | 0.01% | $0 M | Nov 12, 2026 |
| 43 | Tower Research Capital LLC (TRC) | 3,955 | +1,406 (+55.16%) | 0.01% | $0 M | Nov 16, 2026 |
| 44 | Federated Hermes, Inc. | 3,497 | -485 (-12.18%) | 0.01% | $0 M | Nov 12, 2026 |
| 45 | FMR LLC | 2,000 | +600 (+42.86%) | 0.00% | $0 M | Nov 10, 2026 |
| 46 | Jpmorgan Chase & Co | 1,715 | -14,743 (-89.58%) | 0.00% | $0 M | Nov 12, 2026 |
| 47 | BNP Paribas Financial Markets | 595 | -118 (-16.55%) | 0.00% | $0 M | Nov 12, 2026 |
| 48 | SBI Securities Co., Ltd. | 391 | -1 (-0.26%) | 0.00% | $0 M | Oct 22, 2026 |
| 49 | Strategic Wealth Partners, Ltd. | 311 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 50 | Royal Bank Of Canada | 87 | +9 (+11.54%) | 0.00% | $0 M | Nov 16, 2026 |
| 51 | Root Financial Partners, LLC | 85 | New | 0.00% | $0 M | Oct 21, 2026 |
| 52 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding TScan Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.50 M | $1 M | 2.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 575,570 | $1 M | 0.78% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 405,905 | $0 M | 0.55% | 0.04% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 293,642 | $0 M | 0.40% | <0.01% | +8.2% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 167,533 | $0 M | 0.23% | 0.01% | +44% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 87,566 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 72,914 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 69,487 | $0 M | 0.09% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 70,400 | $0 M | 0.09% | 0.05% | −33% | Jun 30, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 65,813 | $0 M | 0.09% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 44,500 | $0 M | 0.06% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 39,000 | $0 M | 0.05% | 0.02% | +36% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 29,612 | $0 M | 0.04% | <0.01% | +2368% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 28,767 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 29,605 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 19,320 | $0 M | 0.03% | <0.01% | −59% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 12,000 | $0 M | 0.02% | <0.01% | +69% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 11,250 | $0 M | 0.02% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,238 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 713 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 303 | $0 M | <0.01% | <0.01% | +13% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 21 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at TScan Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Zoran ZdraveskiSee Remarks | Grant or award | +300,000 | — | — | 304,716 | Form 4 |
| filed | Gavin MacBeathChief Executive Officer, Director | Grant or award | +1.00 M | — | — | 1.05 M | Form 4 |
| filed | Lynx1 Capital Management LP10% owner | Buyindirect | +6,232 | $0.900 | $6 K | 8.02 M | Form 4 |
| filed | Lynx1 Capital Management LP10% owner | Buyindirect | +75,500 | $0.900 | $68 K | 8.01 M | Form 4 |
| filed | Lynx1 Capital Management LP10% owner | Buyindirect | +80,069 | $0.900 | $72 K | 7.94 M | Form 4 |
| filed | Lynx1 Capital Management LP10% owner | Buyindirect | +1.20 M | $1.200 | $1.4 M | 7.95 M | Form 4 |
| filed | Lynx1 Capital Management LP10% owner | Buyindirect | +1.39 M | $1.200 | $1.7 M | 6.75 M | Form 4 |
| filed | Weston Nichols10% owner | Buyindirect | +100,000 | $2.900 | $290 K | 5.36 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: TScan Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 8.2-for-1 split
Fails to deliver
- : 5,562 shares at $0.20
- : 2,526 shares at $0.20
- : 8,909 shares at $0.22
- : 1,951 shares at $0.22
- : 7,835 shares at $0.21
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
TScan Therapeutics, Inc. scorecard#
Passes 6 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.1×Price to book 0.1× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median2.6×Price to sales 2.6× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 5
- ✓Revenue grew in the newest year266.0%Revenue up 266.0% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-8.7%-8.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-8.7%-8.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.00 vs -1.14Diluted EPS -1.00 in fiscal 2025 against -1.14 the year before (report's currency).
- ✗Net income higher than five years earlier-$130 M-$130 M in fiscal 2025 against -$26 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$130 MNet income -$130 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-71.3%-71.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities8.4×Current ratio 8.41 at the end of fiscal 2025.
- ✓Debt below equity0.3×Debt to equity 0.26 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $120 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-49.0×Operating income -49.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-4.20Z-score -4.20 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.9%Diluted shares up 15.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from TScan Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Return on equity | -71.3% | -61.0% | |
| Revenue growth, 3 years a year | -8.7% | 12.9% | |
| Revenue growth | 266.0% | 15.8% | |
| Debt to equity | 0.26× | 0.26× |
2of 8on the Piotroski tests of financial strength
- Net loss of $130 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$140 million.
- The share count rose 15.9% in the year.
- Operating income covers the interest bill only -49.0 times.
TScan Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 10+267%100% | 2.8−86.6%100% | 21+55.5%100% | 14+33.5%100% | 10+835%100% | 1.1—100% | |
| Research and development | 114+6.3%1106% | 107+21.8%3812% | 88+47.4%419% | 60+33.1%442% | 45+118%443% | 21—1896% | |
| General and administrative | 32+5.6%310% | 30+14.9%1076% | 26+29.5%125% | 20+47.2%150% | 14+105%136% | 6.7—621% | |
| Operating expenses | 146+6.2%1415% | 138+20.2%4888% | 115+42.8%544% | 80+36.4%592% | 59+115%580% | 27—2518% | |
| Operating income | −136—−1315% | −135—−4788% | −93—−444% | −67—−492% | −49—−480% | −26—−2418% | |
| Interest expense and finance costs | 2.8−24.2%26.8% | 3.7−2.8%130% | 3.8+220%17.9% | 1.2—8.7% | — | — | |
| Other non-operating income (expense) | 6.0−17.4%58.6% | 7.3+72.7%260% | 4.2+922%20.1% | 0.4+2494%3.1% | 0.0—0.2% | — | |
| Income tax | 0—0.0% | — | — | — | — | — | |
| Net income including minority interests | −130—−1257% | −127—−4528% | −89—−424% | −66—−489% | −49—−479% | −26—−2408% | |
| Net income attributable to shareholders | −130—−1257% | −127—−4528% | −89—−424% | −66—−489% | −49—−479% | −26—−2408% | |
| Earnings per share, basic | -1.00—— | -1.14—— | -1.36—— | -2.75—— | -4.17—— | -28.52—— | |
| Earnings per share, diluted | -1.00—— | -1.14—— | -1.36—— | -2.75—— | -4.17—— | -28.52—— | |
| Shares, weighted average (basic) | 130+15.9%— | 112+70.7%— | 66+173%— | 24+106%— | 12—— | — | |
| Shares, weighted average (diluted) | 130+15.9%— | 112+70.7%— | 66+173%— | 24+106%— | 12+1173%— | 0.9—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 152−14.7%66.6% | 179+34.0%48.1% | 133+11.1%49.0% | 120−25.6%60.3% | 161+364%85.8% | 35—69.9% | |
| Short-term investments | — | 111+89.9%30.0% | 59—21.6% | — | — | — | |
| Other current assets | 4.8+83.8%2.1% | 2.6+19.1%0.7% | 2.2−46.5%0.8% | 4.1−3.5%2.1% | 4.2+157%2.3% | 1.7—3.3% | |
| Current assets | 157−46.3%68.7% | 293+50.7%78.9% | 194+56.5%71.4% | 124−25.1%62.3% | 166+355%88.1% | 36—73.3% | |
| Property, plant and equipment | 8.7+20.2%3.8% | 7.2−6.5%2.0% | 7.7−23.3%2.8% | 10−14.2%5.1% | 12+108%6.3% | 5.7—11.4% | |
| Right-of-use (leased) assets | 58−10.3%25.2% | 64+1.4%17.3% | 63+7.4%23.3% | 59+976%29.7% | 5.5−20.1%2.9% | 6.9—13.8% | |
| Total assets | 229−38.4%100% | 371+36.4%100% | 272+36.7%100% | 199+5.8%100% | 188+278%100% | 50—100% | |
| Accounts payable | 1.2−71.0%0.5% | 4.3+80.2%1.2% | 2.4−18.5%0.9% | 2.9+65.0%1.5% | 1.8−39.3%0.9% | 2.9—5.9% | |
| Debt due within a year | — | — | 3.3—1.2% | — | — | — | |
| Current liabilities | 19−48.0%8.2% | 36+20.6%9.7% | 30+72.3%11.0% | 17−18.9%8.7% | 21+22.3%11.3% | 17—35.1% | |
| Long-term debt | 33+1.4%14.2% | 32+20.1%8.6% | 27−8.8%9.8% | 29—14.7% | — | — | |
| Lease liabilities (non-current) | 54−10.4%23.8% | 61+2.7%16.4% | 59+11.6%21.7% | 53+1107%26.6% | 4.4−27.0%2.3% | 6.0—12.1% | |
| Total liabilities | 106−18.8%46.2% | 130+7.3%35.1% | 121+21.7%44.6% | 100+265%50.1% | 27−16.0%14.5% | 33—65.4% | |
| Retained earnings | −505—−221% | −375—−101% | −248—−91.0% | −158—−79.6% | −92—−49.0% | −44—−87.5% | |
| Shareholders' equity | 123−48.9%53.8% | 241+59.7%64.9% | 151+51.7%55.4% | 99−38.2%49.9% | 161—85.5% | −42—−85.4% | |
| Total liabilities and equity | 229−38.4%100% | 371+36.4%100% | 272+36.7%100% | 199+5.8%100% | 188+278%100% | 50—100% | |
| Shares outstanding | — | — | — | — | — | 1.1—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 2.9−29.3%28.1% | 4.1−24.1%146% | 5.4+5.9%25.7% | 5.1+54.5%37.7% | 3.3+175%32.5% | 1.2—111% | |
| Share-based compensation | 12+22.6%113% | 9.5+83.4%339% | 5.2+14.4%24.7% | 4.6+80.9%33.6% | 2.5+389%24.8% | 0.5—47.5% | |
| Cash from operating activities | −135—−1311% | −111—−3935% | −61—−292% | −67—−491% | −49—−480% | −3.0—−279% | |
| Capital expenditure | −4.4—−42.7% | −3.8—−136% | −3.1—−14.9% | −4.2—−31.2% | −9.9—−98.0% | −4.2—−391% | |
| Cash from investing activities | 109—1059% | −53—−1868% | −61—−289% | −4.2—−31.2% | −9.9—−98.0% | −4.2—−391% | |
| Debt issued | — | — | — | 29—217% | — | — | |
| Shares issued | — | 33−21.9%1177% | 42+21876%202% | 0.2—1.4% | — | — | |
| Cash from financing activities | −0.3−100%−3.3% | 209+54.1%7414% | 135+361%643% | 29−84.5%217% | 190+65757%1870% | 0.3—26.5% | |
| Change in cash | −26−158%−255% | 45+240%1610% | 13—63.3% | −41−132%−306% | 131—1292% | −7.0—−643% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 5.2−38.4%100% | 0.6−76.7%100% | 1.1−65.8%100% | 1.0−54.8%100% | 2.6*+286%100% | 2.5+139%100% | 3.1+474%100% | 2.2+284%100% | 0.7*−90.8%100% | 1.0—100% | 0.5—100% | 0.6—100% | 7.2*—100% | |
| Research and development | 91−26.6%1748% | 25−20.2%4316% | 23−28.3%2227% | 22−26.5%2231% | 20*−31.7%781% | 32+20.7%1262% | 33+21.4%1061% | 30+19.8%1372% | 29*+31.0%4414% | 26—2504% | 27—5014% | 25—4392% | 22*—311% | |
| General and administrative | 31−7.6%599% | 8.3+5.7%1421% | 8.1−10.5%775% | 8.2−4.8%837% | 6.4*−20.4%249% | 7.9+6.3%314% | 9.1+17.0%296% | 8.6+21.9%398% | 8.0*+30.2%1206% | 7.4—706% | 7.8—1450% | 7.1—1251% | 6.2*—85.5% | |
| Operating expenses | 122−22.5%2347% | 34−15.0%5737% | 32−24.4%3001% | 30−21.6%3067% | 26*−29.3%1029% | 40+17.5%1576% | 42+20.4%1357% | 38+20.3%1770% | 37*+30.8%5621% | 34—3210% | 35—6465% | 32—5643% | 29*—396% | |
| Operating income | −117—−2247% | −33—−5637% | −30—−2901% | −29—−2967% | −24*—−929% | −37—−1476% | −39—−1257% | −36—−1670% | −37*—−5521% | −33—−3110% | −34—−6365% | −31—−5543% | −21*—−296% | |
| Interest expense and finance costs | 2.9+0.5%55.2% | 0.8+10.9%132% | 0.7+1.5%66.5% | 0.7+1.5%70.2% | 0.7*−10.5%27.3% | 0.7−27.0%27.8% | 0.7−27.6%22.4% | 0.7−29.2%31.3% | 0.8*−8.0%118% | 1.0—91.3% | 1.0—178% | 1.0—169% | 0.9*—11.8% | |
| Other non-operating income (expense) | 1.4−76.4%27.7% | −0.1−104%−9.2% | 0.1−92.1%12.7% | 0.5−77.7%48.2% | 0.9*−2.4%34.3% | 1.3−50.9%53.4% | 1.7−30.7%55.3% | 2.1+72.5%97.8% | 0.9*−48.2%136% | 2.7—261% | 2.5—458% | 1.2—217% | 1.7*—24.2% | |
| Net income including minority interests | −115—−2219% | −33*—−5646% | −30*—−2889% | −29—−2919% | −23*—−895% | −36*—−1422% | −37*—−1201% | −34—−1572% | −36*—−5385% | −30*—−2849% | −32*—−5907% | −30—−5325% | −20*—−272% | |
| Net income attributable to shareholders | −115—−2219% | −33—−5646% | −30—−2889% | −29—−2919% | −23*—−895% | −36—−1422% | −37—−1201% | −34—−1572% | −36*—−5385% | −30—−2849% | −32—−5907% | −30—−5325% | −20*—−272% | |
| Earnings per share, basic | — | -0.25—— | -0.23—— | -0.22—— | — | -0.28—— | -0.28—— | -0.26—— | — | -0.25—— | -0.28—— | -0.32—— | — | |
| Earnings per share, diluted | — | -0.25—— | -0.23—— | -0.22—— | — | -0.28—— | -0.28—— | -0.26—— | — | -0.25—— | -0.28—— | -0.32—— | — | |
| Shares, weighted average (basic) | 130+0.1%— | 130+0.1%— | 130+0.2%— | 130+0.2%— | — | 130+9.4%— | 130+14.4%— | 130+36.7%— | — | 119—— | 113—— | 95—— | — | |
| Shares, weighted average (diluted) | 130+0.1%— | 130+0.1%— | 130+0.2%— | 130+0.2%— | — | 130+9.4%— | 130+14.4%— | 130+36.7%— | — | 119—— | 113—— | 95—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 73—51.7% | 73−56.9%51.7% | 100−40.9%58.4% | 128−16.9%63.4% | 152−14.7%66.6% | 170+27.3%64.6% | 169−30.0%56.7% | 154+9.7%46.3% | 179+34.0%48.1% | 133—38.2% | 242—64.6% | 141—58.3% | 133—49.0% | |
| Short-term investments | — | — | — | — | — | 15−89.2%5.7% | 49−12.4%16.3% | 98+338%29.3% | 111+89.9%30.0% | 138—39.7% | 56—14.8% | 22—9.2% | 59—21.6% | |
| Other current assets | 3.7—2.6% | 3.7+0.9%2.6% | 4.2+37.7%2.5% | 4.7+49.6%2.3% | 4.8+83.8%2.1% | 3.7+25.2%1.4% | 3.1+66.4%1.0% | 3.1+62.4%0.9% | 2.6+19.1%0.7% | 3.0—0.9% | 1.9—0.5% | 1.9—0.8% | 2.2—0.8% | |
| Current assets | 77—54.3% | 77−59.2%54.3% | 104−52.8%60.9% | 133−47.9%65.7% | 157−46.3%68.7% | 188−31.3%71.8% | 221−26.2%74.1% | 255+54.7%76.6% | 293+50.7%78.9% | 274—78.8% | 300—79.9% | 165—68.4% | 194—71.4% | |
| Property, plant and equipment | 7.1—5.0% | 7.1−23.6%5.0% | 7.7−18.7%4.5% | 8.1−2.8%4.0% | 8.7+20.2%3.8% | 9.3+24.7%3.5% | 9.5+25.0%3.2% | 8.4+16.0%2.5% | 7.2−6.5%2.0% | 7.5—2.1% | 7.6—2.0% | 7.2—3.0% | 7.7—2.8% | |
| Right-of-use (leased) assets | 52—37.1% | 52−11.8%37.1% | 54−11.2%31.6% | 56−10.7%27.7% | 58−10.3%25.2% | 59−0.3%22.7% | 61+0.2%20.5% | 63+0.8%18.9% | 64+1.4%17.3% | 60—17.1% | 61—16.3% | 62—25.8% | 63—23.3% | |
| Total assets | 141—100% | 141−46.1%100% | 171−42.6%100% | 202−39.3%100% | 229−38.4%100% | 262−24.7%100% | 299−20.4%100% | 333+38.1%100% | 371+36.4%100% | 348—100% | 375—100% | 241—100% | 272—100% | |
| Accounts payable | 1.2—0.9% | 1.2−80.5%0.9% | 3.1−31.2%1.8% | 2.3−53.6%1.1% | 1.2−71.0%0.5% | 6.4+74.2%2.4% | 4.5+45.9%1.5% | 5.0+134%1.5% | 4.3+80.2%1.2% | 3.6—1.0% | 3.1—0.8% | 2.1—0.9% | 2.4—0.9% | |
| Debt due within a year | 16—11.1% | 16—11.1% | 12—6.8% | — | — | — | — | — | — | — | 10—2.8% | 6.8—2.8% | 3.3—1.2% | |
| Current liabilities | 38—26.7% | 38+29.5%26.7% | 31−1.1%18.1% | 20−33.0%9.9% | 19−48.0%8.2% | 29+1.9%11.1% | 31−18.8%10.5% | 30−5.3%9.0% | 36+20.6%9.7% | 29—8.2% | 39—10.3% | 31—13.1% | 30—11.0% | |
| Long-term debt | 17—12.2% | 17−46.7%12.2% | 21−34.8%12.3% | 33+1.5%16.2% | 33+1.4%14.2% | 32+5.8%12.4% | 32+60.6%10.8% | 32+37.2%9.7% | 32+20.1%8.6% | 31—8.8% | 20—5.4% | 23—9.7% | 27—9.8% | |
| Lease liabilities (non-current) | 48—34.2% | 48−14.2%34.2% | 50−13.3%29.4% | 52−12.4%26.0% | 54−10.4%23.8% | 56+0.9%21.5% | 58+1.9%19.5% | 60+2.9%18.0% | 61+2.7%16.4% | 56—16.0% | 57—15.2% | 58—24.2% | 59—21.7% | |
| Total liabilities | 103—73.1% | 103−12.5%73.1% | 102−15.9%59.7% | 105−14.2%52.0% | 106−18.8%46.2% | 118−0.6%45.1% | 122+1.8%40.8% | 123+3.9%36.8% | 130+7.3%35.1% | 119—34.2% | 120—31.9% | 118—48.9% | 121—44.6% | |
| Retained earnings | −597—−422% | −597—−422% | −564—−329% | −534—−264% | −505—−221% | −482—−184% | −446—−149% | −409—−123% | −375—−101% | −339—−97.5% | −309—−82.5% | −278—−115% | −248—−91.0% | |
| Shareholders' equity | 38—26.9% | 38−73.6%26.9% | 69−60.9%40.3% | 97−53.9%48.0% | 123−48.9%53.8% | 144−37.1%54.9% | 177−30.8%59.2% | 210+70.9%63.2% | 241+59.7%64.9% | 229—65.8% | 255—68.1% | 123—51.1% | 151—55.4% | |
| Total liabilities and equity | 141—100% | 141−46.1%100% | 171−42.6%100% | 202−39.3%100% | 229−38.4%100% | 262−24.7%100% | 299−20.4%100% | 333+38.1%100% | 371+36.4%100% | 348—100% | 375—100% | 241—100% | 272—100% | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 8.9−28.2%172% | 2.1*−31.0%354% | 2.4*−28.0%224% | 2.5−27.8%251% | 2.0*−26.0%78.2% | 3.0*+19.3%120% | 3.3*+40.6%106% | 3.4+72.1%157% | 2.7*+80.9%408% | 2.5*—241% | 2.3*—434% | 2.0—351% | 1.5*—20.8% | |
| Cash from operating activities | −111—−2138% | −27*—−4621% | −28*—−2620% | −24—−2472% | −32*—−1247% | −32*—−1293% | −33*—−1082% | −38—−1731% | −27*—−4122% | −28*—−2661% | −26*—−4893% | −29—−5171% | −24*—−330% | |
| Capital expenditure | −0.8—−14.9% | −0.0*—−7.0% | −0.5*—−46.9% | −0.1—−7.1% | −0.2*—−6.7% | −1.4*—−56.8% | −1.3*—−41.6% | −1.5—−70.6% | −0.9*—−134% | −1.4*—−131% | −0.9*—−161% | −0.7—−125% | −0.5*—−6.5% | |
| Cash from investing activities | 14−88.3%275% | −0.0*−100%−7.0% | −0.5*−101%−44.2% | −0.1−101%−7.1% | 15*−45.7%578% | 33*—1297% | 48*—1575% | 14−62.6%623% | 27*+1327%4104% | −82*—−7851% | −34*—−6290% | 36—6389% | 1.9*—26.5% | |
| Shares issued | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | |
| Cash from financing activities | — | 0*—0.0% | — | — | 0.1*−99.8%2.8% | 0*−100%0.0% | 0.1*−99.9%3.8% | −0.5−303%−24.2% | 46*+240374%6871% | 1.2*—117% | 162*—30147% | 0.3—45.6% | 0.0*—0.3% | |
| Change in cash | −96−365%−1860% | −27*−24313%−4628% | −28*−283%−2655% | −24—−2480% | −17*−138%−666% | 0.1*—4.5% | 15*−85.0%497% | −25−444%−1132% | 46*—6853% | −109*—−10395% | 102*—18964% | 7.2—1264% | −22*—−303% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What TScan Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$10 M100%+266%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at TScan Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 2 · Directors and officers 7 · Material agreement 3 · Agreement ended 2 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting noticeRestructuringDirectors and officers | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at TScan Therapeutics, Inc.#
16 labor condition applications certified in fiscal 2026 for 16 positions, at a median wage of $104 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Principal Research AssociateMolecular and Cellular Biologists | 3 | $105 K |
| Senior Research AssociateBiochemists and Biophysicists | 3 | $75 K |
| Director, Pharmacovigilance OperationsRegulatory Affairs Managers | 1 | $225 K |
| Manufacturing Associate IIBioengineers and Biomedical Engineers | 1 | $103 K |
| Principal Computational Research AssociateBioinformatics Scientists | 1 | $105 K |
| Principal¿Research¿ScientistMolecular and Cellular Biologists | 1 | $95 K |
| Senior Research Associate, Preclinical DevelopmentMolecular and Cellular Biologists | 1 | $87 K |
| Senior Research Associate, Viral Vector & Discovery PlatformMolecular and Cellular Biologists | 1 | $92 K |
| Senior Supply Chain PlannerLogistics Analysts | 1 | $130 K |
| Sr. Associate, Regulatory AffairsRegulatory Affairs Specialists | 1 | $90 K |
Where: Waltham, MA 16
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 16 | 16 | $104 K | 16 |
| FY2025 | 9 | 9 | $105 K | 9 |
| FY2024 | 4 | 4 | $75 K | 5 |
| FY2023 | 2 | 2 | $88 K | 3 |
| FY2022 | 2 | 2 | $85 K | 2 |
| FY2020 | 1 | 1 | $130 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as TScan Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — | |
| 2025 | · | · | · | · | · | · | · | · | · | · | 66 | · | 66 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 75% of workforce | Restructuring planSEC 8-K | “Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 75% of the Company’s workforce (the “Strategic Reorganization”).” | Filing | |
| 66 people (30% of workforce) | Restructuring planSEC 8-K | “Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How TScan Therapeutics, Inc. compares in Biotechnology
- Market cap$14 M · higher than 13% of 726
- Revenue$10 M · higher than 44% of 647
- Revenue growth266.0% · higher than 91% of 438
- Price / sales2.6× · lower than 80% of 339
- Price / book0.1× · lowest of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| TScan Therapeutics, Inc.🇺🇸 | $14 M | — | — | +266.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 27, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at TScan Therapeutics, Inc.? Verify and update this profile — free
Show TScan Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.